Neurocrine Biosciences (NBIX)

• Market cap: $14.3B
• 1 day: 1.2%
• 5 days: 1.4%
• 1 month: 8.49%
• 3 months: 13.46%
• 6 months: 31.67%
• Year to date: 4.77%
• 1 year: 20.52%
• 5 years: 42.1%
• 10 years: 163.1%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Employees: 1,800

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

50% more funds holding in top 10

Funds holding in top 10: 10 [Q1] → 15 (+5) [Q2]

40% more call options, than puts

Call options by funds: $37.7M | Put options by funds: $27M

18% more capital invested

Capital invested by funds: $10.6B [Q1] → $12.4B (+$1.85B) [Q2]

10% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 69

4.02% more ownership

Funds ownership: 95.71% [Q1] → 99.73% (+4.02%) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 220 | Existing positions reduced: 219

1% less funds holding

Funds holding: 577 [Q1] → 574 (-3) [Q2]

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $141
• Avg. target: $164
• High target: $182

10 analyst ratings

• positive: 9 90%
• neutral: 1 10%
• negative: 0 0%

RBC Capital Brian Abrahams	$149	Outperform Maintained	5 Sep 2025
Morgan Stanley Jeffrey Hung	$163	Overweight Maintained	5 Sep 2025
Guggenheim Yatin Suneja	$175	Buy Maintained	1 Aug 2025
JP Morgan Anupam Rama	$145	Neutral Maintained	31 Jul 2025
Stifel Paul Matteis	$174	Buy Maintained	31 Jul 2025